By Dr. Kiran Kumar Pasam, MD, DM Endocrinology (AIIMS New Delhi), Consultant Endocrinologist, AIG Hospitals and Harmonyx Health, Kokapet, Hyderabad
In short (for patients)
- Diabetes is one of the leading causes of kidney damage, and it is silent until late.
- A simple urine test, the urine albumin-to-creatinine ratio (UACR), together with a blood eGFR, picks up damage early. Get both checked at least once a year.
- Keeping blood pressure and sugar under control protects the kidneys.
- Newer medicines (SGLT2 inhibitors, finerenone and semaglutide) have been shown in large trials to slow kidney damage. Ask your doctor whether they suit you.
- Never stop or change medicines on your own.
1. Why the kidneys need attention in diabetes
High blood sugar and high blood pressure damage the tiny filters (glomeruli) in the kidney over many years. The earliest sign is albumin, a protein, leaking into the urine. At that stage there are usually no symptoms, and the blood creatinine is often still normal. This is why testing matters more than waiting for symptoms.
2. The two tests every person with diabetes needs
UACR (urine albumin-to-creatinine ratio): a spot urine sample. KDIGO classifies it as:
| UACR | Category | Meaning |
|---|---|---|
| Below 30 mg/g | A1 | Normal to mildly increased |
| 30–300 mg/g | A2 | Moderately increased |
| Above 300 mg/g | A3 | Severely increased |
A raised value should be confirmed on repeat testing, because exercise, fever or a urine infection can raise it temporarily.
eGFR (estimated glomerular filtration rate): calculated from blood creatinine. It tells us how well the kidneys are filtering.
Together, UACR and eGFR stage kidney disease and guide treatment. Both are recommended at least once a year in people with diabetes.
3. Blood pressure: the first line of protection
Blood pressure control slows kidney damage more than almost anything else. The 2026 ADA Standards of Care recommend a systolic target below 120 mmHg for people at high cardiovascular or kidney risk, where it can be reached safely. For people with diabetes and albuminuria, an ACE inhibitor or ARB, titrated to the highest tolerated dose, is the foundation (KDIGO 2022).
4. The medicines that changed kidney care
SGLT2 inhibitors
Large trials showed that SGLT2 inhibitors slow the decline in kidney function and reduce kidney failure:
- CREDENCE (canagliflozin, people with type 2 diabetes and kidney disease)
- DAPA-CKD (dapagliflozin, people with CKD with or without diabetes)
- EMPA-KIDNEY (empagliflozin, a broad CKD population)
KDIGO 2022 recommends an SGLT2 inhibitor for people with type 2 diabetes and CKD with an eGFR of 20 mL/min/1.73 m² or more, continued even as kidney function declines, until dialysis or transplant.
Finerenone (a non-steroidal MRA)
In the FIDELIO-DKD trial, finerenone reduced kidney disease progression in people with type 2 diabetes and albuminuria who were already on an ACE inhibitor or ARB. KDIGO suggests it when eGFR is 25 or above, potassium is normal and albuminuria persists despite maximum RAS blockade. The 2026 ADA Standards add that an SGLT2 inhibitor and a non-steroidal MRA can be started together in adults with type 2 diabetes, UACR of 100 mg/g or more and eGFR of 30–90. Potassium needs monitoring.
Semaglutide (GLP-1 receptor agonist)
The FLOW trial (3,533 people with type 2 diabetes and CKD) was the first dedicated kidney-outcome trial of a GLP-1 receptor agonist. Weekly semaglutide 1 mg lowered the risk of the main kidney outcome (kidney failure, a 50% fall in eGFR, or kidney or cardiovascular death) by 24%, and also reduced cardiovascular death and all-cause mortality. The 2026 ADA Standards now include GLP-1 receptor agonists among options for people with type 2 diabetes and CKD.
5. What this means in practice
For a person with type 2 diabetes and kidney involvement, today’s approach usually builds in layers:
- Lifestyle: no smoking, less salt, healthy weight, regular activity.
- Blood pressure control with an ACE inhibitor or ARB.
- An SGLT2 inhibitor.
- Finerenone if albuminuria persists.
- A GLP-1 receptor agonist, especially when weight, sugar or heart risk also need attention.
- Sugar control tailored to the person, with regular UACR, eGFR and potassium checks.
Not every medicine suits every patient. The right combination depends on kidney function, potassium, other illnesses and cost, and should be decided with your doctor.
Frequently asked questions
Do diabetes tablets damage the kidneys?
No. Uncontrolled sugar and blood pressure damage the kidneys. Some diabetes medicines need dose changes when kidney function falls, which is why regular tests matter, but stopping medicines on your own is far more harmful.
How often should I check my kidney function?
At least once a year: a urine UACR and a blood test for creatinine/eGFR. More often if results are abnormal or medicines are changed.
My UACR was 45 mg/g. Do I have kidney disease?
A single raised value needs repeating. If two of three tests over 3–6 months are above 30 mg/g, it indicates kidney involvement, and treatment can slow or even reverse it at this early stage.
Can kidney damage from diabetes be reversed?
Early albumin leakage can often be reduced with good control and the right medicines. Advanced loss of function cannot be reversed, but its progression can be slowed.
This article is for education and does not replace medical advice. Please consult your doctor about your own reports and treatment.
About the author: Dr. Kiran Kumar Pasam is a consultant endocrinologist with a DM in Endocrinology from AIIMS New Delhi. He is Senior Consultant Endocrinologist at AIG Hospitals, Hyderabad, and leads Harmonyx Health, an endocrine and diabetes clinic in Kokapet. He is Secretary of the Endocrine Society of Telangana.
References
- KDIGO Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026, Sections 10 (Cardiovascular Disease and Risk Management) and 11 (Chronic Kidney Disease and Risk Management). Diabetes Care. 2026;49(Suppl 1).
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024. doi:10.1056/NEJMoa2403347.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380:2295–2306.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383:1436–1446.
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–127.
- Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383:2219–2229.